LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors has authoriz…
Category: News
National Vision Announces Settlement of 2025 Convertible Senior Notes
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today announced the settlement of the remaining $84.8 million aggregate principal amount of 2.5% unsecured convertible senior notes due May …
Safe Driving Possible Despite Loss of Visual Field
People who experience a reduced visual field as a result of glaucoma or stroke can drive as safely as those of the same age with normal vision, a recent study finds. Medscape Medical News
Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
GENEVA–(BUSINESS WIRE)–Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
GENEVA–(BUSINESS WIRE)–Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious neu…
GenSight Biologics annonce l’approbation de l’ensemble des résolutions soutenues par le Conseil d’Administration lors de son assemblée générale mixte du 13 mai 2025
PARIS–(BUSINESS WIRE)–Regulatory News: L’Assemblée Générale Mixte des actionnaires de la société GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation…
GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025
PARIS–(BUSINESS WIRE)–Regulatory News: The Combined General Meeting of shareholders of GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies…
Glaukos Announces Participation in Upcoming Investor Conferences
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that i…
This Gender Logs More Eye Surgeries in Residency
Records from more than 4800 ophthalmology residents show the average number of cataract surgeries and other eye procedures could vary by gender and race or ethnicity. Medscape Medical News
ARVO Attendees Hear Call to Save National Eye Institute
An eye research advocacy group has issued an urgent plea to thwart proposals to gut federal funding for biomedical research and dismantle the National Eye Institute. Medscape Medical News
RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today…
How Climate Change Threatens Eye Health
Cataracts, pink eye, and other ocular disorders are linked to heat, air pollution, and higher UV exposure. Knowable Magazine
Cataract Surgery May Be Safe Beyond A1c Cutoffs
Cataract surgery may not increase the risk for postoperative endophthalmitis or severe systemic adverse events in patients with diabetes, regardless of A1c levels, according to a recent study. Medscape Medical News
MHRA Approves First UK Treatment for Thyroid Eye Disease
The Medicines and Healthcare products Regulatory Agency has approved teprotumumab, the first treatment to be licensed in the UK for adults with thyroid eye disease. Medscape News UK
$7.22 Bn OTC Artificial Tears Market Size, Share Analysis, Growth Trends and Forecasts 2024-2025 & 2033 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “OTC Artificial Tears Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033” report has been added to ResearchAndMarkets.com’s offering. The OTC Artificial Tears market is expected to grow from US$ 4….
Vision Care Market Forecast Report and Company Analysis 2025-2033 Featuring Essilor, J&J, Bausch Health, Novartis, Grand Vision, Carl Zeiss, Valeant Pharma, Paragon Vision Science, and Menicon – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Vision Care Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033” report has been added to ResearchAndMarkets.com’s offering. The Vision Care Market is anticipated to rise at a compound annual growt…
Warby Parker Announces First Quarter 2025 Results
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (“Warby Parker” or the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the first quarter ended March 31, 2025. “Our team deliver…
LumiThera’s LIGHTSITE IIIB Extension Trial Topline Results Show Extended Vision Improvement in Dry AMD Subjects
SEATTLE–(BUSINESS WIRE)– #DryAMD–LumiThera’s LIGHTSITE IIIB Extension Trial Topline Results Show Extended Vision Improvement in Dry AMD Subjects Treated with Valeda
Amgen’s TEPEZZA®▼ (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom
CAMBRIDGE, England–(BUSINESS WIRE)–Today, Amgen announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for TEPEZZA® (teprotumumab) as the first therapy specifically licensed for the trea…